Core Viewpoint - Bristol-Myers Squibb Company (NYSE:BMY) is recognized as one of the best stocks for passive income, with a strong history of drug innovation and strategic mergers, focusing on various therapeutic areas [2][4]. Group 1: Company Overview - Bristol-Myers Squibb is a global biopharmaceutical company with a history dating back to the early 1800s, emphasizing drug innovation and strategic mergers [2]. - The company specializes in treatments for oncology, cardiovascular health, immunology, neuroscience, and blood disorders [2]. Group 2: Financial Performance - In recent years, Bristol-Myers Squibb has invested approximately $100 billion in acquisitions to mitigate revenue losses from key drugs nearing patent expiration [3]. - The company declared a quarterly dividend of $0.62 per share on September 17, maintaining its previous dividend level, and has a 16-year track record of dividend growth [4]. - As of September 22, the stock has a dividend yield of 5.51%, making it attractive for passive income investors [4].

Group 1 - AbbVie Inc. (NYSE: ABBV) has experienced a share price increase of 1.7% during the trading session, indicating positive investor sentiment [1] - The potential for further price appreciation exists as investor confidence remains high [1] Group 2 - Manika, a macroeconomist with over 20 years of experience, is involved in investment management and focuses on opportunities in the green economy through her investing group, Green Growth Giants [1]